Daclatasvir (BMS-790052), HCV NS5A protein inhibitor (ab231507)

Overview

  • Product name

    Daclatasvir (BMS-790052), HCV NS5A protein inhibitor
  • Description

    Potent, direct-acting, small molecule inhibitor of HCV NS5A protein
  • Alternative names

    • BMS-790052
  • Biological description

    Daclatasvir a potent, direct acting, small  molecule inhbitor of HCV NS5A protein. It inhbibits replicons expressing a wide range of HCV genotypes with EC50 values in the pM range (9 and 71 pM against the 1b and 2a genotypes, respectively). It also inhibits infection by the JFH-1 genotype 2a virus in cultured cells. Daclatasvir is thought to inhibit relication of the HCV viral genome by affecting the subcellular localization of HCV NS5A and preventing its incorporation into relication complexes. In HCV-infected Huh7 cells, Daclatasvir (1 nM) inhibits viral RNA synthesis and viron assembly. Daclatasvir displays moderate activity against the OAT1B1 (IC50 = 1.5 μM) and OAT1B3 (IC50 = 3.27 μM) organic anion transporters.

  • Purity

    = 97%
  • CAS Number

    1009119-64-5
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    Methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

  • Molecular weight

    738.89
  • Molecular formula

    C40H50N8O6
  • PubChem identifier

    25154714
  • Storage instructions

    Shipped at 4°C. Store at -20°C.
  • Solubility overview

    DMSO = 200.3 mM

    Ethanol = 200.3 mM

     

  • SMILES

    CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
  • Source

    Synthetic

References

This product has been referenced in:

  • Boson B  et al. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites. Gastroenterology 152:895-907.e14 (2017). Read more (PubMed: 27932311) »
  • Gao M  et al. HCV NS5A replication complex inhibitors. Curr Opin Pharmacol 30:151-157 (2016). Read more (PubMed: 27643675) »
  • Furihata T  et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother 58:4555-64 (2014). Read more (PubMed: 24867984) »
  • Guedj J  et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110:3991-6 (2013). Read more (PubMed: 23431163) »
  • Wang C  et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 56:1588-90 (2012). Read more (PubMed: 22203595) »
  • Lee C  et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414:10-8 (2011). Read more (PubMed: 21513964) »
  • Gao M  et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100 (2010). Read more (PubMed: 20410884) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab231507.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up